Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Ex-Roche Campus Reinvented as ‘On3’ Science Center; Developer Seeks to Create Mini-Metropolis in the Suburbs’ for Life Sciences

Nutley, NJ, June 23, 2017 — Owen Proctor reports in The Record/NorthJersey.com that the former Hoffmann-La Roche campus that borders Clifton and Nutley has a new name.

“On3” seeks to incorporate living, working and playing in the Route 3 site, according to Prism Capital Partners’ principal Eugene Diaz. He described the redevelopment as “a mini-metropolis in the suburbs.”

The firm wants to reinvent the 116-acre campus that the pharmaceutical giant began vacating in 2012, creating a synergy among like-minded businesses geared toward life sciences. Continue reading

National Institute on Aging Report: Promising But Inconclusive Evidence on Interventions to Prevent Cognitive Decline, Dementia

Bethesda, MD, June 23, 2017 — The public is enormously concerned about dementia and cognitive impairment, and a wide range of programs and products, such as diets, exercise regimens, games, and supplements, purport to keep these conditions at bay.

It is difficult for individuals, health care providers and policy makers to ascertain what has been demonstrated to prevent or reduce risk.

To help sort through the data and to understand the quality and weight of current evidence for possible interventions, the National Institute on Aging (NIA) at the National Institutes of Health (NIH), commissioned experts for an extensive scientific review and to provide recommendations for public health messaging and future research priorities. Continue reading

NIH Abandons Plans to Limit Individual Research Funding, Creates Special Fund

Washington, DC, June 23, 2017 — After much criticism, the National Institutes of Health (NIH) announced that it will abandon the Grant Support Index (GSI) plan – a strategy to bolster NIH funding support for the next generation of researchers by placing limits on individual research funding which SSTI previously covered.

Instead, NIH will launch the Next Generation Researchers Initiative (NGRI) that will allocate $1.1 billion over the next five years to support nearly 2,400 new grants for early and mid-career researchers whose grant proposals receive high scores, but fall short of receiving funds. Continue reading

Opinion: Allergan Chief Brent Saunders on Helping Our Daughters Stick with STEM (Science, Technology, Engineering & Math)’

Brent L. Saunders

Parsippany, NJ, June 22, 2017Brent L. Saunders, Chairman, President and Chief Executive Officer at Allergan plc, yesterday wrote the following opinion piece on his CEO blog:

As the CEO of a biopharma company that is focused on innovation for patients, I was struck recently by the scientific thinking and discovery happening at an event that might surprise you: my daughter’s high school science fair.

The projects tackled scientific mysteries such as why different shades of color trigger a neurological response including mood, how mathematical statistics explain the so-called “Birthday Paradox” and more. Continue reading

GEN Publishes 2017 Top 10 U.S. Biopharma Clusters List; New Jersey/New York Again Ranked No. 3

New Rochelle, NY, June 22, 2017 — Genetic Engineering & Biotechnology News (GEN) on June 5 published its 2017 Top 10 US Biopharma Clusters list.  New Jersey/New York is number three on the list, the same position it was on GEN’s 2016 Top 10 list.

Greater Philadelphia ranks at number seven.

GEN’s Top 10 U.S. Biopharma Clusters are:

  1. Boston-Cambridge
  2. San Francisco Bay Area
  3. New Jersey/New York
  4. San Diego
  5. Maryland, Virginia and DC Metro
  6. San Diego
  7. Greater Philadelphia
  8. Seattle
  9. Raleigh/Durham (includes Research Triangle Park)
  10. Los Angeles/Orange County
  11. Chicagoland

Continue reading

Choose New Jersey Showcases State’s Assets, Resources at BIO International 2017 This Week

Princeton, NJ, June 22, 2017 — A delegation representing more than 20 New Jersey organizations, including top life sciences companies, universities, trade associations, State government and Choose New Jersey, Inc. is showcasing New Jersey’s assets and resources for biotechnology companies at the New Jersey Pavilion (Booth #1737) at BIO International 2017, June 19-22 (2017) in San Diego, California.

During the world’s largest biotechnology conference, members of the New Jersey delegation are holding business meetings with executives representing companies in North America, Europe and Asia interested in learning more about the benefits of a New Jersey location. Continue reading

Report: $35.6 Billion Invested Globally in University Spinouts Between 2013-2016

Washington, DC, June 22, 2017 — Over the past four years, 1,668 deals involving university spinout companies from across the globe attracted approximately $35.6 billion from 2013 to 2016, according to a new report from Global University Venturing.

The report, however, highlights that global deals peaked in 2014 with 529 deals and total investments dollars peaked in 2015 with nearly $14 billion invested.

As the authors highlighted, these global numbers were unsustainable and 2016 saw significant declines in both deals and dollars. In 2016, the total deals reported were 407 (21.6 percent decrease from 2015) and dollars invested was $6.4 billion (a 54.3 percent decrease from 2015). Continue reading

Center for Venture Research New Report: Angel Dollars and Deals Down in 2016

Durham, NH, June 22, 2017 — The angel investor market in 2016 experienced a decrease in investment dollars and deal size, according to a new report from the Center for Venture Research (CVR) at the University of New Hampshire.

CVR researchers found that total investments were $21.3 billion in 2016, a decrease of 13.5 percent from 2015.

In 2016, a total of 64,380 startups and other entrepreneurial ventures received angel funding – a decline of 9.5 percent from 2016.  Continue reading

Opinion: Labor Leader Greg Lalevee on ‘Workers Win When Jersey Drug Companies Innovate’

Greg Lalevee

Springfield, NJ, June 21, 2017The Record/NorthJersey.com on June 15 published the following opinion piece by Greg Lalevee, Business Manager, the International Union of Operating Engineers Local 825:

New Jersey’s nickname, “Medicine Chest of the World,” is backed up by the numbers.

Our state is home to more than 3,000 life sciences establishments.  Thirteen of the world’s top 20 biopharmaceutical companies have made the Garden State their U.S. headquarters.

These firms are innovating and saving lives every day — and they couldn’t do it without help from supportive government policies and New Jersey’s well-trained and talented union workforce. Continue reading

Seton Hall-Hackensack Meridian School of Medicine Dean Bonita Stanton Featured in ‘Industry Magazine’

Dr. Bonita Stanton

South Orange, NJ, June 21, 2017 — Dean Bonita Stanton, M.D., of the Seton Hall-Hackensack Meridian School of Medicine was interviewed and featured in the June 2017 issue of Industry Magazine.

The article, “Healthcare’s Horizon,” explores the new School of Medicine as a shift in paradigm for both medical pedagogy and health care delivery.

Noting how “The anticipated Seton Hall-Hackensack Meridian School of Medicine will offer an innovative team-based approach that will mirror how healthcare will be delivered in the future,” the article begins: Continue reading